<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="154777">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01991691</url>
  </required_header>
  <id_info>
    <org_study_id>TabPRO I</org_study_id>
    <nct_id>NCT01991691</nct_id>
  </id_info>
  <brief_title>Tablet-based Patient Reported Outcome</brief_title>
  <official_title>Pilot Study for Tablet-based Questionnaire of Patient-reported Outcomes From Patients Undergoing Chemotherapy (TabPRO I)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bonn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bonn</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a single arm feasibility study. Patients that have been diagnosed with
      carcinoma and are undergoing chemotherapy have to document chemotherapy associated side
      effects on a regular basis by means of a tablet-based online questionnaire. Goal of the
      study is to find out if patients that are undergoing chemotherapy are willing to document
      chemotherapy associated side effects by means of a tablet-based online questionnaire.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Feasibility of Tablet-based questionnaire of PRO</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Feasibility of Tablet-based questionnaire of PRO (&gt;60% of patients answer &gt;60% of questionnaires in the time frame of study duration)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Answered questionnaires per patient</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">57</enrollment>
  <condition>Antineoplastic Agents</condition>
  <arm_group>
    <arm_group_label>Tablet-based reported outcome</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>With the start of chemotherapy until the end of the last cycle of chemotherapy the study participants have to document all signs of discomfort or changes to their overall coenesthesia in the tablet-based questionnaire.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tablet-based questionnaire</intervention_name>
    <description>tablet-based patient reported outcomes (TabPRO)</description>
    <arm_group_label>Tablet-based reported outcome</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients have to be â‰¥ 18 years of age

          -  written consent form and agreement to participate in the study

          -  patients that are able to follow the study instructions and that most likely will
             keep the required study appointments

          -  patients that have a histological confirmed carcinoma and are scheduled to undergo
             adjuvant or neoadjuvant chemotherapy of 6 to 8 cycles

          -  questions about chemotherapy associated side effects are composed in german.
             Therefore the study participants must have sufficient knowledge of the german
             language

          -  ECOG maximal level 2

        Exclusion Criteria:

          -  patients that are younger than 18 years

          -  patients that don't agree to take part of the study

          -  patients that are not able to understand the scope, the meaning and the consequences
             of that clinical study

          -  patients that have a known or constant addiction to drugs or alcohol

          -  patients that suffer from blindness or dyslexia
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Mallmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Obstetrics &amp; Gynecology, University Hospital Bonn</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Mallmann, MD</last_name>
    <phone>+49 (0) 228 287 15449</phone>
    <email>michael.mallmann@uni-bonn.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Obstetrics &amp; Gynecology, University Hospital Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Mallmann, MD</last_name>
      <email>michael.mallmann@uni-bonn.de</email>
    </contact>
    <investigator>
      <last_name>Michael Mallmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Obstetrics &amp; Gynecology, University Hospital Cologne</name>
      <address>
        <city>Cologne</city>
        <zip>50931</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marina Wirtz, MD</last_name>
      <phone>+490221 4784910</phone>
      <email>marina.wirtz@uk-koeln.de</email>
    </contact>
    <investigator>
      <last_name>Peter Mallmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Lipscomb J, Gotay CC, Snyder CF. Patient-reported outcomes in cancer: a review of recent research and policy initiatives. CA Cancer J Clin. 2007 Sep-Oct;57(5):278-300. Review.</citation>
    <PMID>17855485</PMID>
  </reference>
  <reference>
    <citation>Dancey J, Zee B, Osoba D, Whitehead M, Lu F, Kaizer L, Latreille J, Pater JL. Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving chemotherapy. The National Cancer Institute of Canada Clinical Trials Group. Qual Life Res. 1997 Mar;6(2):151-8.</citation>
    <PMID>9161115</PMID>
  </reference>
  <reference>
    <citation>Garcia SF, Cella D, Clauser SB, Flynn KE, Lad T, Lai JS, Reeve BB, Smith AW, Stone AA, Weinfurt K. Standardizing patient-reported outcomes assessment in cancer clinical trials: a patient-reported outcomes measurement information system initiative. J Clin Oncol. 2007 Nov 10;25(32):5106-12. Review. Erratum in: J Clin Oncol. 2008 Feb 20;26(6):1018. Lad, Thomas [added].</citation>
    <PMID>17991929</PMID>
  </reference>
  <reference>
    <citation>Basch E, Iasonos A, Barz A, Culkin A, Kris MG, Artz D, Fearn P, Speakman J, Farquhar R, Scher HI, McCabe M, Schrag D. Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. J Clin Oncol. 2007 Dec 1;25(34):5374-80.</citation>
    <PMID>18048818</PMID>
  </reference>
  <reference>
    <citation>Taenzer P, Bultz BD, Carlson LE, Speca M, DeGagne T, Olson K, Doll R, Rosberger Z. Impact of computerized quality of life screening on physician behaviour and patient satisfaction in lung cancer outpatients. Psychooncology. 2000 May-Jun;9(3):203-13.</citation>
    <PMID>10871716</PMID>
  </reference>
  <reference>
    <citation>Roizen MF, Coalson D, Hayward RS, Schmittner J, Thisted RA, Apfelbaum JL, Stocking CB, Cassel CK, Pompei P, Ford DE, et al. Can patients use an automated questionnaire to define their current health status? Med Care. 1992 May;30(5 Suppl):MS74-84.</citation>
    <PMID>1583942</PMID>
  </reference>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 25, 2013</lastchanged_date>
  <firstreceived_date>November 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Bonn</investigator_affiliation>
    <investigator_full_name>Michael Mallmann, MD</investigator_full_name>
    <investigator_title>Coordinating Investigator</investigator_title>
  </responsible_party>
  <keyword>Antineoplastic Agents</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antineoplastic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
